Kitov Pharma is a clinical-stage company that advances first-in-class therapies to overcome tumor-immune evasion and drug resistance in order to create successful, long-lasting treatments for patients with hard-to-treat cancers.
Kitov’s oncology pipeline comprises two drugs. CM-24 is a monoclonal antibody blocking CEACAM1, a novel immune checkpoint that supports tumor-immune evasion and survival through multiple pathways. NT-219 is a potential first-in-class small molecule bi-specific inhibitor of two key cancer resistance pathways – STAT3 and IRS1/2.
Prior to focusing on oncology, Kitov developed Consensi™, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension. The drug was approved by the US Food and Drug Administration (FDA) for marketing in the US in 2018. Consensi™ is expected to be launched in H1 2020 by Kitov’s partner Coeptis Pharmaceuticals. Kitov has also partnered to commercialize Consensi™ in China and South Korea.
CM-24 is a clinical-stage monoclonal antibody blocking CEACAM1, a novel immune checkpoint expressed in multiple tumor types that supports tumor evasion by the immune system through multiple pathways.
The drug is being developed as a combination therapy with anti-PD1 checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC). Kitov plans to initiate Phase 1/2 clinical trials to evaluate the combination of CM-24 with Bristol Myers Squibb’s PD-1 inhibitor nivolumab (Opdivo®) in 2020.
NT-219 is a potential first-in-class small molecule bi-specific inhibitor of two key cancer resistance pathways – STAT3 and IRS1/2.
Kitov plans to submit an Investigational New Drug Application (IND) to the US Food and Drug Administration (FDA) for a clinical study of NT-219 by early 2020. The study will look at NT-219 in combination with cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Kitov plans to initiate the trial immediately after FDA clearance.
Consensi™ is a fixed-dose combination of celecoxib (Celebrex™), a non-steroidal anti-inflammatory drug (NSAID) for the treatment of pain caused by osteoarthritis, and amlodipine besylate (Norvasc™), a drug designed to treat hypertension.
The FDA approved Consensi™ oral tablets for marketing in 2018. Kitov’s US marketing and distribution partner, Coeptis Pharmaceuticals, is expected to launch Consensi™ in H1 2020. Kitov has also partnered to commercialize Consensi™ in China and South Korea.